ArticleCureus2025
Effect of Contrast Media Type on Renal Function in Percutaneous Coronary Intervention (PCI): A Propensity Score-Matched Analysis Considering Contrast Media Volume and Preoperative Renal Function.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective To compare the effects of two low-osmolar contrast media (LOCM), iohexol and iomeprol, on renal function in patients undergoing percutaneous coronary intervention (PCI), as measured by estimated glomerular filtration rate (eGFR). Methods This retrospective study included 180 patients who underwent PCI between January 2021 and December 2022. After propensity score matching based on age, sex, diabetes mellitus, pre-PCI eGFR, contrast media volume, and left ventricular ejection fraction, 88 patients who received either iohexol or iomeprol (44 each) were analyzed. Changes in eGFR at 24 hours and more than 72 hours post-PCI were evaluated. Results There were no differences between the two groups in age [median 71.5 (range 33-86) vs. 73 (range 50-83) years], gender [35 (79.5%) vs. 37 (84.1%) male], pre-PCI eGFR [64.9 (6.8-112.2) vs. 61.3 (8.5-105.2) ml/min/1.73m²], or amount of LOCM used [108 (42-217) vs. 109 (52-222) ml] between the iohexol and iomeprol groups, respectively. No significant differences in absolute or relative changes in eGFR were observed between the two groups at either time point. At 24 hours, the mean relative change in eGFR was 1.6% (-2.5 to 5.8) in the iohexol group and 1.1% (-2.8 to 4.9) in the iomeprol group. At more than 72 hours, relative changes were -2.1% (-5.9 to 1.7) and -0.3% (-4.4 to 3.8), respectively. No cases of post-contrast acute kidney injury were observed. Conclusion Changes in renal function after PCI did not differ significantly between iohexol and iomeprol, despite differences in osmolality and viscosity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.